有争议的过去,烂的现在,不可预测的未来:阿尔茨海默氏症病史的简要回顾
Félix Bermejo-Pareja1,2, Teodoro Del Ser3
1CIBERNED, Institute of Health Carlos III, 28029 Madrid, Spain.
Journal of clinical medicine
|January 23, 2024
概括
阿尔茨海默病 (AD) 的概念已经显著发展. 目前的理解缺乏共识,虽然痴呆症发病率可能正在下降,但需要重新评估AD.
科学领域:
- 神经学 神经学
- 病理学 病理学 病理学
- 老年学是一门学科.
背景情况:
- 自发现以来,阿尔茨海默氏症 (AD) 的概念已经发展.
- 直到20世纪70年代,阿尔茨海默病被认为是罕见的,然后获得了显著的研究兴趣.
- 现代AD理解受到生物标志物和粉样蛋白假设的影响.
研究的目的:
- 审查阿尔茨海默病的历史和当前概念.
- 讨论AD鼻科和诊断模型的演变.
- 分析AD研究中生物标志物和治疗结果的影响.
主要方法:
- 经典叙事审查方法.
- 文献选择优先考虑Medline最佳匹配.
- 讨论历史和当代AD研究结果.
主要成果:
- 随着时间的推移,AD概念经历了大量的修改.
- 临床病理学模型和粉样蛋白假设主导着目前的AD理解.
- 生物标志物的发展支持了新的AD定义,但治疗方法在很大程度上失败了;痴呆的发病率可能正在下降.
结论:
- 目前关于阿尔茨海默病的概念缺乏普遍共识.
- 复杂的AD生理病理学,与衰老交织在一起,有多个相互竞争的假设.
- 虽然减少痴呆症发病率是有希望的,但重新评估AD概念是必不可少的.
相关概念视频
Alzheimer's Disease: Overview
490
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
490
Alzheimer's Disease: Treatment
195
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
195
Dementia
115
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
115
Parkinson's Disease: Overview
551
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
551
Amnesia
127
Amnesia is a condition marked by long-term memory loss, which impairs the ability to recall past events or create new memories.
The severity and duration of memory loss vary depending on the type and underlying cause. Amnesia is classified into two main types: retrograde and anterograde.
Retrograde amnesia is marked by the loss of memories formed before the onset of the condition. Patients may recall distant past events but often forget those occurring shortly before the incident.
Anterograde...
The severity and duration of memory loss vary depending on the type and underlying cause. Amnesia is classified into two main types: retrograde and anterograde.
Retrograde amnesia is marked by the loss of memories formed before the onset of the condition. Patients may recall distant past events but often forget those occurring shortly before the incident.
Anterograde...
127
Amyloid Fibrils
9.5K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.5K


